| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hippocampus | 48 | 2019 | 225 | 6.790 |
Why?
|
| Neurons | 47 | 2024 | 491 | 5.410 |
Why?
|
| Memory | 24 | 2017 | 216 | 3.380 |
Why?
|
| Action Potentials | 37 | 2019 | 220 | 3.100 |
Why?
|
| Models, Neurological | 34 | 2019 | 145 | 2.960 |
Why?
|
| Psychomotor Performance | 13 | 2018 | 116 | 1.970 |
Why?
|
| Nerve Net | 17 | 2019 | 141 | 1.930 |
Why?
|
| Prefrontal Cortex | 10 | 2014 | 90 | 1.820 |
Why?
|
| Cannabinoids | 11 | 2017 | 55 | 1.780 |
Why?
|
| Memory, Short-Term | 9 | 2018 | 68 | 1.480 |
Why?
|
| Animals | 79 | 2023 | 8544 | 1.340 |
Why?
|
| Rats | 43 | 2017 | 1946 | 1.230 |
Why?
|
| Nonlinear Dynamics | 29 | 2019 | 77 | 1.220 |
Why?
|
| Macaca mulatta | 21 | 2019 | 355 | 1.200 |
Why?
|
| Receptor, Cannabinoid, CB1 | 11 | 2015 | 68 | 1.140 |
Why?
|
| Cognition | 10 | 2016 | 576 | 1.130 |
Why?
|
| CA1 Region, Hippocampal | 17 | 2017 | 41 | 1.090 |
Why?
|
| Endocannabinoids | 6 | 2011 | 43 | 1.060 |
Why?
|
| Electrodes, Implanted | 12 | 2018 | 57 | 1.030 |
Why?
|
| Rats, Long-Evans | 22 | 2017 | 92 | 1.000 |
Why?
|
| CA3 Region, Hippocampal | 14 | 2017 | 28 | 0.970 |
Why?
|
| Behavior, Animal | 15 | 2017 | 303 | 0.760 |
Why?
|
| Prostheses and Implants | 4 | 2016 | 53 | 0.620 |
Why?
|
| Electric Stimulation | 9 | 2013 | 139 | 0.620 |
Why?
|
| Male | 44 | 2019 | 20697 | 0.580 |
Why?
|
| Reward | 3 | 2010 | 70 | 0.580 |
Why?
|
| Cognition Disorders | 5 | 2012 | 390 | 0.580 |
Why?
|
| Pyrazoles | 11 | 2015 | 81 | 0.580 |
Why?
|
| Learning | 4 | 2013 | 88 | 0.570 |
Why?
|
| Pyramidal Cells | 4 | 2011 | 19 | 0.560 |
Why?
|
| Synaptic Transmission | 6 | 2016 | 125 | 0.560 |
Why?
|
| Neural Pathways | 9 | 2014 | 116 | 0.550 |
Why?
|
| Mental Recall | 1 | 2018 | 52 | 0.540 |
Why?
|
| Brain Mapping | 5 | 2010 | 208 | 0.540 |
Why?
|
| Computer Simulation | 14 | 2019 | 250 | 0.500 |
Why?
|
| Morpholines | 10 | 2015 | 46 | 0.490 |
Why?
|
| Sleep Deprivation | 4 | 2010 | 12 | 0.480 |
Why?
|
| Benzoxazines | 9 | 2015 | 28 | 0.480 |
Why?
|
| Piperidines | 11 | 2015 | 141 | 0.480 |
Why?
|
| Naphthalenes | 9 | 2015 | 53 | 0.470 |
Why?
|
| Neuronal Plasticity | 3 | 2017 | 86 | 0.450 |
Why?
|
| Journalism | 1 | 2015 | 1 | 0.450 |
Why?
|
| Information Storage and Retrieval | 2 | 2012 | 28 | 0.450 |
Why?
|
| Memory Disorders | 5 | 2016 | 58 | 0.450 |
Why?
|
| Brain | 9 | 2024 | 1031 | 0.440 |
Why?
|
| Neurosciences | 1 | 2015 | 11 | 0.440 |
Why?
|
| Reaction Time | 6 | 2010 | 131 | 0.430 |
Why?
|
| Glutamic Acid | 2 | 2014 | 50 | 0.400 |
Why?
|
| Ceramics | 1 | 2013 | 7 | 0.390 |
Why?
|
| Biofeedback, Psychology | 1 | 2012 | 12 | 0.370 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 2 | 2017 | 39 | 0.360 |
Why?
|
| Models, Theoretical | 4 | 2012 | 145 | 0.360 |
Why?
|
| Cortical Synchronization | 1 | 2011 | 3 | 0.350 |
Why?
|
| Nootropic Agents | 2 | 2008 | 14 | 0.350 |
Why?
|
| Behavior | 2 | 2010 | 31 | 0.340 |
Why?
|
| Electrophysiology | 5 | 2012 | 77 | 0.320 |
Why?
|
| Pupil | 1 | 2010 | 4 | 0.320 |
Why?
|
| Cell Movement | 1 | 2010 | 180 | 0.310 |
Why?
|
| Photic Stimulation | 5 | 2014 | 172 | 0.310 |
Why?
|
| Neurophysiology | 1 | 2009 | 11 | 0.300 |
Why?
|
| Isoxazoles | 1 | 2008 | 7 | 0.290 |
Why?
|
| Microelectrodes | 4 | 2016 | 20 | 0.290 |
Why?
|
| Radiation Injuries, Experimental | 2 | 2019 | 38 | 0.280 |
Why?
|
| Frontal Lobe | 2 | 2023 | 41 | 0.280 |
Why?
|
| Task Performance and Analysis | 6 | 2017 | 54 | 0.280 |
Why?
|
| Neural Inhibition | 3 | 2017 | 35 | 0.280 |
Why?
|
| Serial Learning | 1 | 2008 | 2 | 0.280 |
Why?
|
| Sympathomimetics | 1 | 2007 | 5 | 0.270 |
Why?
|
| Neuropeptides | 1 | 2007 | 23 | 0.270 |
Why?
|
| Humans | 26 | 2024 | 34475 | 0.270 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2007 | 86 | 0.270 |
Why?
|
| Signal Processing, Computer-Assisted | 6 | 2014 | 48 | 0.260 |
Why?
|
| Electric Stimulation Therapy | 2 | 2018 | 19 | 0.260 |
Why?
|
| Cocaine | 5 | 2012 | 355 | 0.260 |
Why?
|
| Receptors, Drug | 3 | 2003 | 21 | 0.260 |
Why?
|
| Brain Injuries | 2 | 2018 | 94 | 0.250 |
Why?
|
| Deep Brain Stimulation | 4 | 2015 | 53 | 0.250 |
Why?
|
| Rats, Sprague-Dawley | 6 | 2014 | 923 | 0.250 |
Why?
|
| Receptors, Cannabinoid | 5 | 2011 | 35 | 0.250 |
Why?
|
| Analysis of Variance | 5 | 2014 | 508 | 0.250 |
Why?
|
| Prosthesis Design | 5 | 2016 | 116 | 0.240 |
Why?
|
| Postural Balance | 2 | 2016 | 152 | 0.220 |
Why?
|
| Epilepsy | 2 | 2017 | 86 | 0.220 |
Why?
|
| Cerebral Cortex | 4 | 2011 | 146 | 0.220 |
Why?
|
| Calcium | 5 | 2013 | 343 | 0.220 |
Why?
|
| Pattern Recognition, Visual | 1 | 2004 | 12 | 0.210 |
Why?
|
| Lidocaine | 2 | 2005 | 20 | 0.210 |
Why?
|
| Ultrasonics | 1 | 2023 | 22 | 0.210 |
Why?
|
| Motor Activity | 6 | 2015 | 356 | 0.200 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2014 | 755 | 0.200 |
Why?
|
| Drug Tolerance | 2 | 2003 | 41 | 0.200 |
Why?
|
| Pesticides | 1 | 2016 | 201 | 0.200 |
Why?
|
| Occupational Exposure | 1 | 2016 | 237 | 0.200 |
Why?
|
| Synapses | 2 | 2017 | 89 | 0.190 |
Why?
|
| Receptors, GABA-A | 1 | 2003 | 33 | 0.190 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 248 | 0.190 |
Why?
|
| Marijuana Abuse | 1 | 2003 | 20 | 0.190 |
Why?
|
| Nucleus Accumbens | 1 | 2004 | 121 | 0.190 |
Why?
|
| Transients and Migrants | 1 | 2016 | 304 | 0.190 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2003 | 83 | 0.190 |
Why?
|
| Executive Function | 2 | 2013 | 60 | 0.190 |
Why?
|
| Substance-Related Disorders | 1 | 2004 | 140 | 0.190 |
Why?
|
| Random Allocation | 2 | 2013 | 257 | 0.190 |
Why?
|
| Space Perception | 3 | 2007 | 30 | 0.180 |
Why?
|
| Arachidonic Acids | 2 | 2011 | 28 | 0.170 |
Why?
|
| Carbamates | 2 | 2011 | 18 | 0.170 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2012 | 58 | 0.170 |
Why?
|
| Benzamides | 2 | 2011 | 59 | 0.170 |
Why?
|
| Algorithms | 9 | 2018 | 560 | 0.160 |
Why?
|
| Positron-Emission Tomography | 3 | 2012 | 176 | 0.160 |
Why?
|
| Acetylcholine | 2 | 2010 | 69 | 0.160 |
Why?
|
| Hispanic Americans | 1 | 2016 | 948 | 0.160 |
Why?
|
| Electrophysiological Phenomena | 3 | 2013 | 31 | 0.140 |
Why?
|
| Fibronectins | 1 | 2018 | 40 | 0.140 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2018 | 62 | 0.140 |
Why?
|
| Time Factors | 6 | 2019 | 2352 | 0.140 |
Why?
|
| Cerebrovascular Circulation | 1 | 2018 | 104 | 0.130 |
Why?
|
| Seizures | 1 | 2018 | 67 | 0.130 |
Why?
|
| Endothelium, Vascular | 1 | 2018 | 163 | 0.130 |
Why?
|
| Receptors, AMPA | 2 | 2008 | 16 | 0.130 |
Why?
|
| Likelihood Functions | 3 | 2013 | 52 | 0.130 |
Why?
|
| Glucose | 2 | 2008 | 194 | 0.130 |
Why?
|
| Data Interpretation, Statistical | 3 | 2012 | 123 | 0.120 |
Why?
|
| Cerebrovascular Disorders | 1 | 2017 | 55 | 0.120 |
Why?
|
| Cranial Irradiation | 1 | 2017 | 95 | 0.120 |
Why?
|
| Extracellular Matrix | 1 | 2018 | 260 | 0.120 |
Why?
|
| Radiation Injuries | 1 | 2017 | 86 | 0.120 |
Why?
|
| Biological Clocks | 1 | 2015 | 6 | 0.120 |
Why?
|
| Baclofen | 2 | 2013 | 28 | 0.120 |
Why?
|
| Equipment Design | 4 | 2009 | 192 | 0.110 |
Why?
|
| Pattern Recognition, Physiological | 1 | 2014 | 4 | 0.110 |
Why?
|
| Electrodes | 2 | 2013 | 20 | 0.110 |
Why?
|
| Probability Theory | 1 | 2014 | 2 | 0.110 |
Why?
|
| History, 21st Century | 1 | 2015 | 63 | 0.110 |
Why?
|
| History, 20th Century | 1 | 2015 | 76 | 0.110 |
Why?
|
| Glycine | 2 | 2013 | 31 | 0.110 |
Why?
|
| Psychotropic Drugs | 1 | 2014 | 12 | 0.110 |
Why?
|
| Sleep | 1 | 2015 | 90 | 0.110 |
Why?
|
| Neuropsychological Tests | 3 | 2010 | 372 | 0.110 |
Why?
|
| Maze Learning | 3 | 2010 | 16 | 0.100 |
Why?
|
| Spatial Behavior | 2 | 2013 | 12 | 0.100 |
Why?
|
| Neuroprotective Agents | 2 | 2005 | 34 | 0.100 |
Why?
|
| Feeding Behavior | 1 | 2015 | 168 | 0.100 |
Why?
|
| Radiopharmaceuticals | 2 | 2012 | 103 | 0.100 |
Why?
|
| Monte Carlo Method | 3 | 2014 | 25 | 0.100 |
Why?
|
| User-Computer Interface | 2 | 2011 | 55 | 0.100 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2013 | 4 | 0.100 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2013 | 8 | 0.100 |
Why?
|
| Corpus Striatum | 2 | 2013 | 75 | 0.100 |
Why?
|
| Injections, Intravenous | 2 | 2012 | 101 | 0.090 |
Why?
|
| Perception | 1 | 2013 | 107 | 0.090 |
Why?
|
| Primates | 3 | 2023 | 130 | 0.090 |
Why?
|
| ROC Curve | 4 | 2014 | 176 | 0.090 |
Why?
|
| Electroencephalography | 3 | 2018 | 76 | 0.090 |
Why?
|
| Information Theory | 1 | 2011 | 4 | 0.090 |
Why?
|
| Pattern Recognition, Automated | 1 | 2012 | 38 | 0.090 |
Why?
|
| Polyunsaturated Alkamides | 1 | 2011 | 12 | 0.090 |
Why?
|
| Cell Communication | 1 | 2011 | 42 | 0.090 |
Why?
|
| Glycerides | 1 | 2011 | 14 | 0.090 |
Why?
|
| Biphenyl Compounds | 1 | 2011 | 21 | 0.090 |
Why?
|
| Injections | 1 | 2011 | 76 | 0.090 |
Why?
|
| 6-Cyano-7-nitroquinoxaline-2,3-dione | 1 | 2011 | 3 | 0.090 |
Why?
|
| Second Messenger Systems | 1 | 2011 | 8 | 0.090 |
Why?
|
| Wakefulness | 2 | 2015 | 30 | 0.080 |
Why?
|
| Ryanodine Receptor Calcium Release Channel | 1 | 2011 | 21 | 0.080 |
Why?
|
| Rodentia | 1 | 2011 | 10 | 0.080 |
Why?
|
| Macaca | 1 | 2010 | 30 | 0.080 |
Why?
|
| Phosphorylation | 1 | 2011 | 264 | 0.080 |
Why?
|
| Eye Movements | 1 | 2010 | 16 | 0.080 |
Why?
|
| Telemetry | 1 | 2009 | 30 | 0.080 |
Why?
|
| Exploratory Behavior | 1 | 2009 | 34 | 0.070 |
Why?
|
| Video Recording | 1 | 2009 | 64 | 0.070 |
Why?
|
| Brain Chemistry | 1 | 2008 | 46 | 0.070 |
Why?
|
| Microscopy, Confocal | 1 | 2008 | 80 | 0.070 |
Why?
|
| Decision Making | 1 | 2010 | 203 | 0.070 |
Why?
|
| Cocaine-Related Disorders | 1 | 2009 | 125 | 0.070 |
Why?
|
| Administration, Intranasal | 1 | 2007 | 36 | 0.070 |
Why?
|
| Discriminant Analysis | 1 | 2007 | 22 | 0.070 |
Why?
|
| Tetrahydrocannabinol | 1 | 2007 | 1 | 0.070 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2008 | 259 | 0.060 |
Why?
|
| omega-Conotoxin GVIA | 2 | 2005 | 7 | 0.060 |
Why?
|
| Oxazoles | 2 | 2005 | 7 | 0.060 |
Why?
|
| Calcium Channel Blockers | 2 | 2005 | 54 | 0.060 |
Why?
|
| Orientation | 1 | 2006 | 29 | 0.060 |
Why?
|
| Aging | 1 | 2013 | 1010 | 0.060 |
Why?
|
| Multivariate Analysis | 1 | 2007 | 703 | 0.060 |
Why?
|
| Therapy, Computer-Assisted | 1 | 2005 | 5 | 0.060 |
Why?
|
| Biomimetics | 1 | 2005 | 7 | 0.060 |
Why?
|
| Ryanodine | 1 | 2005 | 4 | 0.060 |
Why?
|
| Methylmercury Compounds | 1 | 2004 | 4 | 0.050 |
Why?
|
| Cytosol | 1 | 2004 | 27 | 0.050 |
Why?
|
| Phospholipases A | 1 | 2004 | 31 | 0.050 |
Why?
|
| Arachidonic Acid | 1 | 2004 | 41 | 0.050 |
Why?
|
| Transducers | 1 | 2023 | 15 | 0.050 |
Why?
|
| Reproducibility of Results | 3 | 2014 | 819 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2016 | 924 | 0.050 |
Why?
|
| Hand | 1 | 2004 | 80 | 0.050 |
Why?
|
| Saccades | 1 | 2023 | 25 | 0.050 |
Why?
|
| Marine Toxins | 1 | 2003 | 4 | 0.050 |
Why?
|
| Sodium Channel Blockers | 1 | 2003 | 7 | 0.050 |
Why?
|
| Enzyme Activators | 1 | 2003 | 8 | 0.050 |
Why?
|
| Interneurons | 1 | 2003 | 24 | 0.050 |
Why?
|
| GABA Antagonists | 1 | 2003 | 14 | 0.050 |
Why?
|
| Anesthetics, Local | 1 | 2004 | 96 | 0.050 |
Why?
|
| Patch-Clamp Techniques | 1 | 2003 | 77 | 0.050 |
Why?
|
| GABA Agonists | 1 | 2003 | 11 | 0.050 |
Why?
|
| Receptors, GABA-B | 1 | 2003 | 19 | 0.050 |
Why?
|
| Adaptation, Physiological | 1 | 2003 | 58 | 0.050 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2003 | 76 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2003 | 185 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2003 | 306 | 0.050 |
Why?
|
| Statistics, Nonparametric | 2 | 2014 | 138 | 0.040 |
Why?
|
| North Carolina | 1 | 2016 | 1612 | 0.040 |
Why?
|
| Cyclohexanols | 2 | 2015 | 22 | 0.040 |
Why?
|
| Models, Statistical | 3 | 2007 | 193 | 0.040 |
Why?
|
| Dizocilpine Maleate | 2 | 2011 | 10 | 0.040 |
Why?
|
| Excitatory Amino Acid Antagonists | 2 | 2011 | 29 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 612 | 0.040 |
Why?
|
| Linear Models | 2 | 2013 | 464 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2002 | 526 | 0.040 |
Why?
|
| Disease Models, Animal | 3 | 2010 | 1118 | 0.040 |
Why?
|
| Dopamine Uptake Inhibitors | 2 | 2012 | 147 | 0.040 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2019 | 83 | 0.040 |
Why?
|
| Adult | 2 | 2016 | 10015 | 0.040 |
Why?
|
| Receptors, GABA | 1 | 2017 | 7 | 0.030 |
Why?
|
| Drug Interactions | 2 | 2010 | 90 | 0.030 |
Why?
|
| Normal Distribution | 2 | 2009 | 14 | 0.030 |
Why?
|
| Vision, Ocular | 1 | 2017 | 33 | 0.030 |
Why?
|
| Temporal Lobe | 1 | 2017 | 35 | 0.030 |
Why?
|
| Gene Expression | 1 | 2018 | 362 | 0.030 |
Why?
|
| Computational Biology | 1 | 2017 | 100 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2017 | 110 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 1 | 2017 | 129 | 0.030 |
Why?
|
| Feedback, Physiological | 1 | 2015 | 12 | 0.030 |
Why?
|
| Sleep, REM | 1 | 2015 | 6 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2014 | 35 | 0.030 |
Why?
|
| Oxotremorine | 1 | 2013 | 4 | 0.020 |
Why?
|
| Resorcinols | 1 | 2013 | 7 | 0.020 |
Why?
|
| Muscarinic Agonists | 1 | 2013 | 8 | 0.020 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 2013 | 18 | 0.020 |
Why?
|
| Concept Formation | 1 | 2013 | 4 | 0.020 |
Why?
|
| Aged | 1 | 2016 | 10999 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 834 | 0.020 |
Why?
|
| Analog-Digital Conversion | 1 | 2012 | 2 | 0.020 |
Why?
|
| Amplifiers, Electronic | 1 | 2012 | 3 | 0.020 |
Why?
|
| Electronics | 1 | 2012 | 15 | 0.020 |
Why?
|
| Middle Aged | 1 | 2016 | 12703 | 0.020 |
Why?
|
| Computer Systems | 1 | 2011 | 15 | 0.020 |
Why?
|
| Online Systems | 1 | 2011 | 12 | 0.020 |
Why?
|
| Ligands | 1 | 2011 | 97 | 0.020 |
Why?
|
| Phenylcarbamates | 1 | 2010 | 3 | 0.020 |
Why?
|
| Receptor Cross-Talk | 1 | 2010 | 4 | 0.020 |
Why?
|
| Acetylcholinesterase | 1 | 2010 | 20 | 0.020 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2010 | 42 | 0.020 |
Why?
|
| Cholinergic Antagonists | 1 | 2010 | 10 | 0.020 |
Why?
|
| Scopolamine | 1 | 2010 | 8 | 0.020 |
Why?
|
| Feedback, Sensory | 1 | 2010 | 3 | 0.020 |
Why?
|
| Dopamine | 1 | 2012 | 268 | 0.020 |
Why?
|
| Reinforcement (Psychology) | 1 | 2009 | 3 | 0.020 |
Why?
|
| Evoked Potentials | 1 | 2009 | 19 | 0.020 |
Why?
|
| Uncertainty | 1 | 2009 | 12 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2004 | 765 | 0.020 |
Why?
|
| Basal Ganglia | 1 | 2009 | 23 | 0.020 |
Why?
|
| Mice | 1 | 2015 | 2691 | 0.020 |
Why?
|
| Swimming | 1 | 2007 | 7 | 0.020 |
Why?
|
| Female | 1 | 2016 | 21491 | 0.020 |
Why?
|
| Extinction, Psychological | 1 | 2007 | 17 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 2007 | 51 | 0.020 |
Why?
|
| Microinjections | 1 | 2007 | 39 | 0.020 |
Why?
|
| Stochastic Processes | 1 | 2006 | 5 | 0.010 |
Why?
|
| Dendrites | 1 | 2006 | 17 | 0.010 |
Why?
|
| Equipment Failure Analysis | 1 | 2005 | 47 | 0.010 |
Why?
|
| Macrocyclic Compounds | 1 | 2005 | 2 | 0.010 |
Why?
|
| Dantrolene | 1 | 2005 | 3 | 0.010 |
Why?
|
| Estrenes | 1 | 2005 | 3 | 0.010 |
Why?
|
| Thionucleotides | 1 | 2005 | 5 | 0.010 |
Why?
|
| Okadaic Acid | 1 | 2005 | 6 | 0.010 |
Why?
|
| Pyrrolidinones | 1 | 2005 | 6 | 0.010 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2005 | 34 | 0.010 |
Why?
|
| N-Methylaspartate | 1 | 2005 | 14 | 0.010 |
Why?
|
| Rats, Inbred Strains | 1 | 2005 | 77 | 0.010 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2005 | 20 | 0.010 |
Why?
|
| Cell Death | 1 | 2005 | 84 | 0.010 |
Why?
|
| Calcium Signaling | 1 | 2005 | 49 | 0.010 |
Why?
|
| Cyclic AMP | 1 | 2005 | 56 | 0.010 |
Why?
|
| Artificial Intelligence | 1 | 2005 | 66 | 0.010 |
Why?
|
| Fetus | 1 | 2005 | 91 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2005 | 177 | 0.010 |
Why?
|
| Phospholipases A2 | 1 | 2004 | 25 | 0.010 |
Why?
|
| Cannabis | 1 | 2004 | 29 | 0.010 |
Why?
|
| Research | 1 | 2004 | 88 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2002 | 31 | 0.010 |
Why?
|
| GTP-Binding Proteins | 1 | 2002 | 40 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2002 | 175 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2004 | 887 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2002 | 192 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2002 | 341 | 0.010 |
Why?
|